STOCKHOLM--(BUSINESS WIRE)--Regulatory News: RaySearch Laboratories AB (publ.)(STO:RAYB) has entered into a license agreement with GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt, Germany (GSI) regarding techniques for calculating radiobiological effective dose in ion beam treatments. Ion beam therapy is the most advanced form of external radiotherapy where the tumor is irradiated with protons or carbon ions. Compared to conventional radiotherapy, where the tumor is irradiated with photons, the energy deposition of the ion beams can be controlled much more effectively. This means that the radiation dose can be delivered even more precisely and as a result, the unwanted dose to healthy tissues can be reduced, leading to a reduction of treatment-related side effects. However, the biological effect of ions on tissue is different compared to traditional photon beams and this difference must be accounted for during treatment planning for ion beams.
